Abstract
INTRODUCTION
Low back pain is a common symptom in elderly due to spine degeneration process which is termed as osteo arthritis (OA) of the lumbar. The prevalence of OA both in men and women at 50 years are alike, while prevalence in over 50 years are increasing in women. However, the etiology remains unknown. Numerous factors are thought to be the cause of low back pain, such as estrogen changes that often occur in older women at post menopause [1] . Low back pain in postmenopausal women is a clinical manifestation of degeneration process over the most mobile spine main areas/segments. Lumbar OA is the degeneration of cartilage which involves three joints complex that are characterized by narrowing of the lumbar intervertebral disc, vertebral osteophytes formation and occurrence of OA in the facet joints [2, 3] . These pathological processes can be resulted from mechanical stress loads due to weight gain and aging that will lead to cartilage thinning, as well as inflammatory process.
Inflammatory process that occurs in the lumbar OA is a chronic inflammatory process which involve the role of cytokines, either proinflammatory cytokines such as interleukin (IL)6, or antiinflammatory cytokines such as IL1ra or IL10. Production of IL6 by human chondrocytes are also affected by estradiol, suggesting the possibility of a mechanism that affect the metabolism of cartilage [4] . Increased IL6 will facilitate degeneration process and stimulates the formation of osteoclast precursors of granulocyte macrophage colonyforming units and incr ease the number of osteoclasts in vivo which leads to increase bone resorption, contributes to the change in spondiloarthrosis [5] . IL6 are also produced by fat cells. Inhibitors of IL6 (including estrogen) are used for the treatment of osteoporosis in postmenopausal women [6] . IL6 also plays an important role in bone metabolism via induction of osteoclastogenesis and stimulates osteoclast activity [7] . IL6 increases the formation of osteoclasts, especially when estrogen levels decline [8] . IL6 stimulates formation of osteoclast precursors of granulocyte macro phage colonyforming units and increases the number of osteoclasts in vivo, leading to increased bone resorption, which contributes to spondiloarthrosis and degeneration of intervertebral discs [5] . Increasing amount of IL6 in patients with aging and menopause are suspected that IL6 is one of cytokine which plays an important role in the process of bone resorption, by affecting activity of osteoclasts, including the subkondral bone, followed by destruction of cartilage [5] . IL10 is formerly known as cytokine synthesis inhibitory factor, plays an important role as an antiinflammatory and immunosuppressive cytokines. IL10 is produced from regulatory of T cells, also produced by a large number of other cells including macrophages [9] . IL10 is very effective when suppressing macrophages to release tumor necrosis factor (TNF)α [5] . Degradation of cartilage resulting in increasing level of cartilage oligomeric matrix protein (COMP) in synovial fluid and serum. The products of cartilage degradation will be fagocyted by the synovium and stimulate the inflammatory process. Synovium cells are activated and produce various catabolic, proinflammatory mediators and proteolytic enzymes which will cause cartilage damage [10] . Increased of COMP level indicates an increase in cartilage damage, as well as the IL6 increasing the number of osteoclasts which leads to increased bone resorption including subchondral bone [11] . Estrogen deficiency will affect the metabolism of the chondrocytes.
In post-menopausal women with estrogen deficiency prone to have cartilage damage. It is supported by the study of the OA prevalence in postmenopausal women with and without hormone replacement therapy (HRT) showed strong evidence of the benefits of estrogen on OA. Identification over two estrogen receptors: ERα and ERb proves that the cartilage chondrocytes sensitive to estrogen [1] . Several in vivo and in vitro studies showed that chondrocytes respond to estrogen and its mechanisms that affect the metabolism of the chondrocytes [3, 12] . To date, it is still unclear whether high levels of COMP and IL6 and low level of IL10 in postmenopausal women with estrogen deficiency could be determined as risk factors for symptomatic lumbar OA. In this study, the authors aimed to prove that the COMP, IL6 and IL10 are risk factors for symptomatic lumbar OA in postmenopausal women with estrogen deficiency. By determining the role of COMP, IL6 and IL10 as risk factors for the occurrence of symptomatic lumbar OA in postmenopausal women estrogen deficiency, it is expected that early prediction, prevention and management can be recognized in the future.
MATERIALS AND METHODS
The study was conducted from October 2015 until March 2016 at Sanglah General Hospital, Denpasar, Bali. The aim of this study was to determine the role of COMP, IL6, IL10 and IL6 to IL10 ratio as risk factors of lumbar symptomatic OA in postmenopausal women with estrogen deficiency.
This was a case control study with consecutive sampling method. It started with identification for group of cases which was defined as postmenopausal women with estrogen deficiency and symptomatic lumbar OA. The pair of the cases was taken with control group, which was defined as postmenopausal women with estrogen deficiency and asymptomatic lumbar OA. The independent variables were measured retrospectively. The analysis continued with comparison of exposure probability to risk factors. The case group later compared with the control group to describe baseline characteristics and analyzed using two by two table to obtain odds ratio (OR). Odds ratio described as the risk effects, which result from exposure to the risk factors.
Forty four postmenopausal women from the po pulation were identified and defined for both cases and controls and matched by age and body mass index. The blood sampling was performed to measure serum COMP levels and plasma cytokine levels consisting of IL6 and IL-10 using ELISA. The obtained data were analyzed for normality and the characteristics of cases and controls equality were analyzed by comparing the mean length of menopause, age, BMI and estrogen levels. Analysis of risk factors for symptomatic lumbar OA performed with bivariate analysis (McNemar's Chi Square). The risk estimation was calculated with OR.
RESULTS
Subjects in this study were aged 57 years old in average, with BMI of 25.8 kg/m 2 and length of menopause about 6 years with the levels of estrogen approximately 15 pg/ mL (Table 1) . By using the serum COMP levels of 0.946 as the cutoff point, the OR between symptomatic lumbar OA in postmenopausal women with estrogen deficiency and asymptomatic lumbar OA was 0.7 (95%CI: 0.261 to 1.751), and statistically not significant with P value of < 0.05 (P = 0.393) ( Table 2 ). This suggests that postmenopausal women with estrogen deficiency and high levels of serum COMP is not a risk factor for symptomatic lumbar OA. Whereas, by using the plasma IL6 levels of 2.264 as the cutoff point, the OR between symptomatic lumbar OA and asymptomatic lumbar OA in postmenopausal women with estrogen deficiency was 2.7 (95%CI: 0.991 to 8.320) with P < 0.05 (P = 0.033) ( Table 2 and Figure 1 ). This suggest that postmenopausal women with estrogen deficiency who had high levels of plasma IL6 were associated with increased risk for symptomatic lumbar OA with calculated risk 2.7 times than those having low levels of plasma IL6.
The risk difference was statistically significant with P < 0.05. By using the plasma IL-10 levels of 6.049 as the cutoff point, the OR between symptomatic lumbar OA and asymptomatic lumbar OA in postmenopausal women with estrogen deficiency was 0.6 (95%CI: 0.209 to 1.798) with P > 0.05 (P = 0.345). This suggests that low levels of plasma IL10 in postmenopausal women with estrogen deficiency was not a risk factor for symptomatic lumbar OA (Table 2) .
Using the ratio levels of plasma IL6/IL10 0.364 as the cutoff point, the OR between symptomatic lumbar OA in postmenopausal women with estrogen deficiency and asymptomatic lumbar OA was 3.4 (95%CI: 1.204 to 11.787) with P value of < 0.05 (P = 0.011) ( Table  2 and Figure 2 ). This suggest that high ratio of plasma IL6/IL10 in postmenopausal women with estrogen deficiency had significantly higher risk for symptomatic lumbar OA with calculated risk 23.4 times than those having low ratio of plasma IL6/IL10.
DISCUSSION
Postmenopausal women who enrolled in the study were aged 58 years old in average, most of them had BMI category of overweight, length of menopause about 6 years and estrogen deficiency.
According to Richette et al [1] (2003), there is a relationship between estrogen decline and progression of OA, and it was found that its prevalence increases over age 50 years. Suyasa IK and Setiawan IGNY (2016) also found relationship of aging, BMI and estrogen deficiency with symptomatic lumbar OA [13] . The lumbar OA defined as a degeneration of cartilage which involves three joint complexes which characterized by narrowing of lumbar intervertebral disc, vertebral osteophytes formation and occurrence of OA in facet joints. These pathological conditions potentially caused by mechanical stress load due to aging, weight gain and hormonal changes that occur in joint cartilage thinning process [3] . Two estrogen receptors: ERα and ERb, identified in chondrocytes and has proven sensitive to estrogen. In vivo animal studies showed that intraarticular injection of estrogen have a dose dependent; supraphysiological dose of 17β estradiol histologically induces OA histologically, on the other hand, it had no effect when given in low dose. In postmenopausal women, estrogen may decrease the speed of subchondral bone remodelling, which is a key factor in the pathophysiology of OA. Furthermore, estrogen receptor expression was shown in sinoviocytes, which are targets effect of estrogen on the joints [1, 3, 5] .
Role of serum COMP levels in symptomatic lumbar OA
In this study, the levels of serum COMP was not signi ficantly with different risk for symptomatic lumbar OA with OR of 0.7 (95%CI: 0.261 to 1.751; P = 0.393). These results are in contrast to recent research by Goode et al [11] (2012) regarding the relationship between narrowing of the intervertebral discs, COMP and low back pain. Among patients with low back pain, strong correlations between COMP and narrowing of the intervertebral discs was found with OR of 1.82 (95%CI: 1:02 to 3:27). These finding reflects the degeneration of the intervertebral disc which characterized by narrowing of the intervertebral discs and any other symptoms associated with degeneration process [11] . COMP is a noncollagen protein which originated from cartilage extracellular matrix, act as a prognostic marker for OA. The levels of COMP can be used to predict the severity of damage in large joints, in addition, it can also predict the narrowing gap of joints [14] . As a biomarker, the concentration of COMP in synovial fluid or serum can be used as an indicator of early abnormalities [15, 16] , thus, COMP is very sensitive to detect early occurrence of premature OA in patients whom genetically suffering from OA [17] . OA is characterized by the destruction of cartilage and subchondral bone. Similarly, in lumbar OA which involved three joint complex, those pathological changes will occur in the cartilage of facet joint. Cartilage damage can be induced by mechanical factors, in which antigen release by the joint cartilage occurred. This situation will stimulate immune system, causing immunological reaction such as release of inflammatory mediators and proteases that are destructive and can aggravate the cartilage damage [11] . Cartilage damage characterized by the increase levels of COMP. As a diagnosis indicator, COMP correlated with disease severity. It is proved by detection of COMP levels 10 times higher in the synovial fluid of patients with OA.
Degradation of cartilage resulted in increased levels of COMP in synovial fluid and serum. These cartilage degradation products will be fagocyted by the synovium and stimulate inflammatory process. Synovium cells are activated and produce various catabolic and proin flammatory mediators and proteolytic enzymes which will lead to cartilage damage [10] . However, serum COMP levels can not be stated as a specific indicator that reflects the facet joint cartilage damage because serum COMP levels generally increased as a result of damage to the cartilage in the various joints of the body. This is in correspond with research of Söderlin et al [18] (2004), which stated that increase in serum COMP levels is a common finding in OA that indicate cartilage involvement. These are due to the narrow facet cartilage surface area and the serum COMP does not fully describe the extent of cartilage damage. According to Neidhart et al [19] (1997), serum COMP levels constantly lower in the synovial fluid than cartilage matrix, so that taking samples from cartilage matrix might provide more accurate results. In addition, the concept of three joint complex in the lumbar OA involves only a small portion of cartilage in the facet joints, because 2/3 of load movement in one single functional unit is in the anterior unit [19] . The levels of serum COMP in this study gathered due to differences in OA stages of the subjects as well as differences in affinity or specificity of primary antibody used in the detection of COMP. Western blot analysis with the mAbs 12C4 showed higher affinity towards COMP fragments which had low molecular weight compared to mAbs 14G4 [20] . According to Tseng et al [21] (2009), specificity of COMP against cartilage and specific reagent for degradation of COMP is still lacking. These conditions would limit its usefulness in determining the presence of OA as well as for the examination of dichotomous out come in the population (normal vs abnormal) [21] . Another study by Lohmander et al [22] (1994) also stated that high concentration of COMP can be found only at the early stages of OA development and not at the advanced stage. According to Mobasheri and Henrotin [23] (2011), COMP has the ability to mediate interaction between chondrocytes and cartilage extracellular matrix. COMP suppresses apoptosis in primary chondrocytes through activation of caspase3 and induction of apoptosis inhibitor protein family (IAP) on survival proteins such as Baculoviral IAP Repeat Containing 3 and 5, X-linked IAP (BIRC3, BIRC5, XIAP). This is certainly in accordance with the study where investigated that COMP may be a protective factor against Symptomatic lumbar OA although not proven to be statistically significant.
The role of IL-6 plasma levels in symptomatic lumbar OA
In this study, IL6 plasma levels were high (above median) in postmenopausal women with estrogen deficiency. This finding suggested that high levels of IL-6 plasma significantly act as a risk factor for symptomatic lumbar OA with OR of 2.7 (95%CI: 0.991 to 8.320; P = 0.033). This finding was in line with the study of Weber et al [24] (2016) and Valdes [25] (2010), that IL6
was significantly higher in patients with low back pain (LBP), moreover, IL-6, BMI, duration of symptoms and age were significantly correlated with low back pain. IL-1, IL-6 and IL-10 that involved in the inflammatory process were also correlated with the risk of OA. IL6 is a cytokine that acts as an innate and acquired immunity, formed by many cells and affect multiple targets. The main sources of IL6 are macrophages and lymphocytes in inflammatory area. IL6 also plays an important role in enhancing the formation of osteoclasts, especially when estrogen levels are declining [8] . IL6 stimulates formation of osteoclast precursors of granulocyte macrophage colonyforming units and increase the number of osteoclasts in vivo, leading to increased bone resorption, which contributed to spondiloarthrosis and degeneration of intervertebral discs [5] . While Ershler, Harman and Keller [7] (2002) found an increase in IL6 on aging and menopausal women. The levels of IL6 increased in older age [26] and significantly increased at the age of 70 [27] . In OA, the production of IL6 is mainly stimulated by increased catabolic cytokines that are IL1 and TNFα, and then IL6 will potentiate the effect of IL1. In the pathogenesis of OA, IL6 has dual functions that are as a trigger of the inflammatory process and has the ability to downregulate the factors involved catabolic role in the degeneration of cartilage [28] . In addition, IL6 is also plays an important role in bone resorption including subchondral bone through the activity of osteoclasts.
The role of IL6 plasma against symptomatic lumbar OA is through the activation of transducer glycoprotein 130 (gp130) on neurons due to the formation of complex IL6/soluble IL6R. Transducer glycoprotein 130 (gp130) is associated with sensitization taste buds of pain through activation of phosphoinositide 3kinase, protein kinase Cdelta and Janus kinase as well as the regulation of ion channel transient receptor potential cation channels vanilloid 1 (TRPV1) [29] . IL6 is regarded as a key cytokine, which cause changes in the subchondral bone layer. The effect is largely based on the formation of osteoclasts resulting in bone resorption and also showed synergism with IL-1β and TNF [30] .
Plasma levels of IL-10 in symptomatic lumbar OA
In this study, the plasma levels of IL10 were not proven to be significant as a risk factor for symptomatic lumbar OA with OR of 0.6 (95%CI: 0.209 to 1.798; P = 0.345). This is in contrast with the study by John et al [31] (2007) and Wang et al [32] (2001) which found that IL10 not only inhibits the synthesis of inflammatory cytokines, but also protect the chondrocytes directly to antagonize the role of IL1. Immunoregulatory cytokine IL10 modulates a series of apoptosis in TNFα such as caspase activity in human articular chondrocytes. IL10, known as cytokine synthesis inhibitory factor, is an antiinflammatory and immunosuppressive cytokine, produced by Tregulatory cells and macrophages. IL10 is a cytokine that is highly effective on suppressing the release of TNFα by macrophages. There are two main functions of IL10 such as inhibit the production of several cytokines (TNF, IL1, and the chemokine IL12) and inhibit the function of macrophages and dendritic cells in the activation of Tcell, generally it has an immunosuppressive effect. Supression on macrophage function occurs because IL10 suppressing the expression of MHC class Ⅱ molecules on macrophages, and reduce the expression of co-stimulatory (a.l. B7-1 and B7-2). The final impact of IL10 activities is specific and nonspecific supression of inflammatory reactions which mediated by Tcells. According to those, IL10 known as cytokine synthesis inhibitory factor and anti-inflammatory cytokines [9] . IL10 also able to show chondroprotective effect in the course of OA. Chondrocytes express the cytokines IL10 and IL10R receptor. It has been proven that IL10 is involved in stimulating the synthesis of collagen type II and aggrecan. After administration of IL10 in vitro, the healthy articular cartilage over the course of OA showed increased in proteoglycan synthesis and its percentage in the extracellular matrix. IL10 inhibits apoptosis of chondrocytes, which might be a result of stimulation on IL1b antagonist synthesis, IL1Ra, tissue inhibitor of metalloproteinase1 (TIMP1) and growth factors. IL10 reduces the effect of TNFα in synovial fibroblasts in patients with OA [16] . In lumbar OA, IL10 alone can not be used as a risk factor, because the inflammatory process is chronic involving via complex interaction by various cytokines, both proinflammatory cytokines such as TNFα and IL-6, as well as cytokines anti-inflammatory such as IL1ra or IL10. Increased levels of TNFα and IL6 will be responded by anti-inflammatory cytokines. IL-10 is very powerful suppressor for TNFα released by macrophages. The low levels of IL10 can be used as an indicator of failure in the process of TNFα and IL6 suppression.
The role of IL10 plasma in symptomatic lumbar OA is a protective factor although not clearly proved. To determine the role of IL10 levels as a risk factor, it can be evaluated on the expression of IL10 ratio against other potential cytokines such as ratio of IL6/IL10 [33] .
The ratio of plasma levels IL-6 / IL-10 in symptomatic lumbar OA In this study, the ratio levels of plasma IL6/IL10 were high (above median) in postmenopausal women estrogen deficiency. This finding showed that high ratio levels of plasma IL6/IL10 significantly acts as a risk factor for symptomatic lumbar OA with OR of 3.4 (95%CI: 1.204 to 11.787; P = 0.011). The results of this study showed the concept of balance between proinflammatory cytokines and antiinflammatory cytokines. Until now, data and research on the ratio of IL6/IL10 in symptomatic lumbar OA in postmenopausal women with estrogen deficiency does not exist. And the role of inflammatory and anti inflammatory cytokines in the pathogenesis of OA on inter and intracellular signaling pathways are still under study [30] . Based on the explanation, the levels of IL-6 or IL-10 alone did not reflect the existence of symptomatic lumbar OA in postmenopausal women with estrogen deficiency. The ratio of both IL6 and IL10 is required to obtain more accurate result and reflect incidence of symptomatic lumbar OA in postmenopausal women with estrogen deficiency.
The role of the IL6 to IL10 ratio levels against symptomatic lumbar OA is through the interaction of pro inflammatory cytokines with anti-inflammatory cytokines.
Both of these cytokines potentially provide accurate information on the risk of symptomatic lumbar OA. IL6 plasma has a function as a trigger of the inflammatory process and has the ability to downregulation the catabolic factors that involved in cartilage degeneration, while IL-10 inhibits specific and non-specific inflammatory reactions as a response to the increase of cytokines TNFα and IL6.
From the data analysis that had been done in this study, it is concluded that the high ratio of IL6/IL10 plasma levels is the strongest risk factor of symptomatic lumbar OA in postmenopausal women with estrogen deficiency.
Plasma COMP can not be considered as a biomarker of symptomatic lumbar OA in postmenopausal women with estrogen deficiency.
COMMENTS

Background
Lumbar osteoarthritis (OA) is the degeneration of cartilage which involves three joint complex. Indeed, the inflammatory process, which is a chronic inflammatory process, influence this pathological process especially if alteration of estrogen levels occurs. Furthermore, degradation of cartilage lead to increased cartilage oligomeric matrix protein (COMP) levels. Either proinflammatory cytokines [interleukin (IL)-6] or anti-inflammatory cytokines (IL-1ra or IL-10) and COMP are thought to be relevant as risk factor for symptomatic lumbar OA in postmenopausal women with estrogen deficiency.
Research frontiers
IL-6, IL-10, and COMP had been extensively studied in relation to inflammatory process and cartilage damage. Chronic inflammatory process occurs in individuals with lumbar OA and this inflammatory process related to estrogen levels. Thus, it is of interest whether IL-6, IL-10, and COMP are risk factors for symptomatic lumbar OA in postmenopausal women with estrogen deficiency.
